- Home
- NXGL vs APVO Comparison
NXGL vs APVO Comparison
Compare NXGL & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXGL | APVO |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | United States | United States |
| Employees | 19 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8M | 8.3M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | NXGL | APVO |
|---|---|---|
| Price | $0.82 | $4.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 203.2K | 34.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,114,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $42.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $0.25 |
| 52 Week High | $3.25 | $13.11 |
Technical Indicators
Market Signals| Indicator | NXGL | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 33.55 | 35.09 |
| Support Level | N/A | $2.85 |
| Resistance Level | $2.73 | $5.59 |
| Average True Range (ATR) | 0.14 | 0.49 |
| MACD | -0.02 | -0.26 |
| Stochastic Oscillator | 19.69 | 21.59 |
Price Performance
Historical ComparisonAbout NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.